US 11,717,491 B2
Solid nanoparticle with inorganic coating
Jan-Otto Carlsson, Uppsala (SE); Anders Johansson, Uppsala (SE); and Marten Rooth, Knivsta (SE)
Assigned to NANEXA AB, Uppsala (SE)
Filed by Nanexa AB, Uppsala (SE)
Filed on Nov. 12, 2020, as Appl. No. 17/96,511.
Application 17/096,511 is a continuation of application No. 16/654,648, filed on Oct. 16, 2019, granted, now 10,864,171.
Application 16/654,648 is a continuation of application No. 15/645,073, filed on Jul. 10, 2017, granted, now 10,478,402, issued on Nov. 19, 2019.
Application 15/645,073 is a continuation of application No. 14/891,398, abandoned, previously published as PCT/EP2014/060746, filed on May 23, 2014.
Claims priority of application No. 13169219 (EP), filed on May 24, 2013.
Prior Publication US 2021/0121415 A1, Apr. 29, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/51 (2006.01); A61K 9/50 (2006.01)
CPC A61K 9/5192 (2013.01) [A61K 9/5073 (2013.01); A61K 9/5115 (2013.01)] 31 Claims
 
1. A method of preparing a controlled or delayed release pharmaceutical composition comprising:
i. a plurality of coated particles of a size that is from 0.1 μm to 50 μm, said coated particles having a solid core comprising a biologically active substance, said solid core being enclosed by one or more coatings comprising zinc oxide; and
ii. a pharmaceutically acceptable carrier, the method comprising the sequential steps of:
(1) applying an initial coating comprising zinc oxide to said solid cores in an atomic layer deposition reactor;
(2) discharging the coated particles from the reactor and subjecting the coated particles to agitation to disaggregate particle aggregates formed during step (1);
(3) reintroducing the disaggregated, coated particles from step (2) into an atomic layer deposition reactor and applying a further coating comprising zinc oxide to the reintroduced particles;
(4) optionally repeating steps (2) and (3) one or more times to increase total thickness of the coatings comprising zinc oxide that enclose said solid core; and
(5) admixing said coated particles obtained from step (3) or step (4) with said pharmaceutically acceptable carrier to form said pharmaceutical composition.